Product Program year 2024 Source: CMS Open Payments

Procalcitonin

Device Infectious Disease

Open in the dashboard

General payments

$213,227

429 payments

Research payments

$0

0 payments

Through program year 2024, $213,227 in general payments and $0 in research payments were reported against Procalcitonin (Infectious Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2024 General $50,241 113
2023 General $72,800 107
2021 General $34,482 69
2019 General $55,703 140

Breakdown

Who paid General payments · program years 2019–2024
  1. Fisher Scientific Company L.L.C. $213,227 429 payments
Top recipients General payments · program year 2024
  1. Padmashree Woodham Maternal & Fetal Medicine · Macon, GA $9,780 19% · 5 payments
  2. Subbian Karumanchi Nephrology · Boston, MA $5,970 12% · 5 payments
  3. Thomas File Infectious Disease · Akron, OH $4,665 9% · 9 payments
  4. Scott Weiss Pediatric Critical Care Medicine · Philadelphia, PA $4,416 9% · 3 payments
  5. Anders Berg Clinical Pathology/Laboratory Medicine · Boston, MA $4,000 8% · 2 payments

The top 5 of 76 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Maternal & Fetal Medicine Obstetrics & Gynecology $11,840 24% · 10 practitioners
  2. Infectious Disease Internal Medicine $7,165 14% · 2 practitioners
  3. Critical Care Medicine Internal Medicine $7,015 14% · 3 practitioners
  4. Nephrology Internal Medicine $5,970 12% · 1 practitioner
  5. Pediatric Critical Care Medicine Pediatrics $4,416 9% · 1 practitioner

The top 5 of 24 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Massachusetts $9,970 20% · 2 recipients
  2. Georgia $9,780 19% · 1 recipient
  3. Illinois $5,376 11% · 2 recipients
  4. Texas $5,018 10% · 13 recipients
  5. Ohio $4,665 9% · 1 recipient

The top 5 of 22 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

429 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record